Back to Stacks
Muscle GrowthRecoveryAnecdotal

CJC-1295 + Ipamorelin + BPC-157: Recovery & GH

A popular performance and recovery stack combining the GH secretagogue synergy of CJC-1295 and Ipamorelin with BPC-157's direct tissue healing and anti-inflammatory effects. The GH component supports protein synthesis, body composition, and systemic recovery, while BPC-157 targets localised tissue repair, tendon and ligament healing, and gut integrity. This three-peptide combination is widely used by athletes seeking both systemic anabolic support and targeted injury recovery simultaneously.

Safety Notes

All three are unapproved research compounds. The CJC-1295 and Ipamorelin components are contraindicated in active or hormone-sensitive malignancies due to GH stimulation. BPC-157 has demonstrated pro-angiogenic properties in animal models, extending the malignancy caution to the full stack. No formal safety data exists for this triple combination; each compound's individual risk profile applies independently.

Peptides in This Stack

  1. 1
    BPC-157Recovery

    The primary localised repair agent, targeting tendon, ligament, and muscle healing while also supporting gut integrity — the most common acute recovery bottleneck in high-load training contexts.

  2. 2
    CJC-1295Fat Loss

    Provides the GHRH backbone for sustained GH secretion, supporting systemic protein synthesis, body composition, and broader recovery alongside BPC-157's targeted tissue repair.

  3. 3
    IpamorelinPerformance

    Complements CJC-1295 with selective ghrelin-receptor stimulation to enhance GH pulse amplitude while avoiding the cortisol and prolactin elevation associated with less selective secretagogues.

Research References

Emerging

  • Prolonged stimulation of GH and IGF-I secretion by CJC-1295J Clin Endocrinol Metab 2006 · PMID 16822960Per-component source only — no combination study exists
  • Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol 1998 · PMID 9849822Per-component source only — no combination study exists
  • Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tractCurr Pharm Des 2011 · PMID 21548867Per-component source only — no combination study exists

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.